Pelthos Therapeutics Inc. (PTHS) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pelthos Therapeutics Inc. (PTHS:NYSE), powered by AI.
- Current Price
- $20.40
- P/E Ratio
- -1.4
- Market Cap
- 11M
- Sector
- Healthcare
What is the Pelthos Therapeutics Inc. stock price forecast?
Pelthos Therapeutics Inc. is currently trading at $20.40. View real-time AI analysis on Alpha Lenz.
What is Pelthos Therapeutics Inc. insider trading activity?
View the latest insider trading data for Pelthos Therapeutics Inc. on Alpha Lenz.
What is Pelthos Therapeutics Inc.'s P/E ratio?
Pelthos Therapeutics Inc.'s P/E ratio is -1.4.
Pelthos Therapeutics Inc.
“Pelthos Therapeutics Inc. trades at a P/E of -1.4 (undervalued) with strong ROE of 293.1%.”
Ask for details →Company Overview
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs. Its primary function is to develop and launch treatments like ZELSUVMI™, a novel therapeutic product for Molluscum contagiosum infections. Notably, Pelthos Therapeutics leverages its proprietary nitric oxide-based technology platform to address significant medical challenges. The company operates in the pharmaceutical sector, specifically targeting dermatological conditions. With a strong pipeline of potential product candidates, Pelthos aims to deliver impactful treatments to patients across various demographics. Its market significance lies in addressing unmet medical needs through pioneering therapeutic innovations.
Company Statistics
(FY 2024)Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Pelthos Therapeutics Inc. trades at a P/E of -1.4 (undervalued) with strong ROE of 293.1%.”
Ask for details →